Welcome to our dedicated page for Sangamo Therapeutics SEC filings (Ticker: SGMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sangamo Therapeutics, Inc. (SGMO) SEC filings page on Stock Titan provides direct access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI‑generated summaries that help explain their contents. Sangamo is a genomic medicine company listed on the Nasdaq Capital Market, and its filings document clinical, regulatory, financial and listing‑related developments across its Fabry disease and neurology‑focused pipeline.
Investors can review Sangamo’s current reports on Form 8‑K, which the company uses to report material events. Recent 8‑Ks describe positive topline and updated data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST‑920) in Fabry disease, including mean annualized estimated glomerular filtration rate (eGFR) slopes and safety findings, as well as the FDA’s agreement to use eGFR slope as an endpoint for an accelerated approval pathway. Other 8‑Ks cover quarterly financial results, collaboration and license agreements, executive transitions and a Nasdaq notice granting additional time to regain compliance with the minimum bid price requirement.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available in the feed) provide more detailed information on Sangamo’s research and development expenses, general and administrative costs, cash and cash equivalents, and risk factors related to its genomic medicine programs, collaborations and capital needs. These filings also elaborate on the company’s description of its business as a neurology‑focused genomic medicine company and its reliance on investigational product candidates such as ST‑920, ST‑503 and ST‑506.
On this page, Stock Titan’s tools surface new SGMO filings from EDGAR in near real time and apply AI‑powered analysis to highlight key points, such as clinical endpoints referenced in 8‑Ks, updates on BLA preparation activities, or disclosures about Nasdaq listing compliance. Users can also locate proxy statements and other governance‑related documents to better understand Sangamo’s executive compensation plans and board‑level decisions, as referenced in its SEC filings. This combination of source documents and AI summaries is intended to make it easier to interpret complex regulatory language without replacing the need to read the original filings.
Sangamo Therapeutics (SGMO) reported positive topline data from its registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease. In 32 treated adults, a single infusion produced a mean annualized eGFR slope of +1.965 mL/min/1.73 m²/year at 52 weeks, contrasting with published slopes of -2.2 to -0.4 mL/min for current standard therapies. Among 19 patients with 104-week follow-up, the slope remained positive at +1.747 mL/min, the FDA-endorsed intermediate endpoint for Accelerated Approval.
Secondary outcomes were uniformly favorable. All 18 patients initially on enzyme-replacement therapy discontinued ERT and remained off treatment, while plasma lyso-Gb3, cardiac parameters and α-Gal A activity stayed stable or improved for up to 4.5 years. Patient-reported outcomes showed statistically significant gains across multiple SF-36 domains and reductions in gastrointestinal symptoms, pain-medication use and anhidrosis.
Safety profile appeared benign: most adverse events were grade 1-2; no pre-conditioning, no safety-related discontinuations. The most common TEAEs were pyrexia (60.6%), COVID-19 (36.4%), headache (33.3%) and nasopharyngitis (33.3%).
The dataset supports SGMO’s plan to file a BLA under the Accelerated Approval pathway as early as Q1 2026. ST-920 already holds Orphan Drug, Fast Track and RMAT designations, plus EU and UK incentives. Full analyses will be presented at a future conference, and management is pursuing a commercialization partnership.